Skip to content
  • Global Key Solutions is now KeyPedia →
  • Independent Study of FDA Correspondence Finds Earliest CDER Warning Letter Citing AI Use →
  • KeyPedia Launches openFDA MCP Connector With an "Elsa for Industry" Approach →
  • KeyPedia Listed in TPRA’s TPRM Tools List →
  • Global Key Solutions is now KeyPedia →
  • Independent Study of FDA Correspondence Finds Earliest CDER Warning Letter Citing AI Use →
  • KeyPedia Launches openFDA MCP Connector With an "Elsa for Industry" Approach →
  • KeyPedia Listed in TPRA’s TPRM Tools List →
KeyPediaKeyPedia
  • Company
  • Platform
  • Media
  • KeyPedia Lite
  1. Home
  2. /
  3. Records
  4. /
  5. Fda Inspections
  6. /
  7. Aurobindo Pharma USA Inc
FDA Inspection•Aurobindo Pharma USA Inc•July 29, 2011

Aurobindo Pharma USA Inc – FDA Inspection, Jul 29, 2011

Record Details

This FDA Inspection record concerns Aurobindo Pharma USA Inc, with an inspection on July 29, 2011, issued by the Center for Drug Evaluation and Research, covering drugs.

Company
Aurobindo Pharma USA Inc
Inspection Date
July 29, 2011
Product Type
Drugs
Office
Center for Drug Evaluation and Research

ID · bacfcc10-9940-4b19-9084-4bb60639c9f3

Inspection Facts

Voluntary Action Indicated (VAI)

Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.

Inspection number
736360
FDA center
Human Drugs
Project area
Bioresearch Monitoring

FDA Citations

6
  1. 21 CFR 314.80(b)Failure to review ADE information
  2. 21 CFR 314.81(b)(1)(ii)Contamination, chemical or physical change, deterioration
  3. 21 CFR 314.80(c)(1)(ii)Submission of report follow-up
  4. 21 CFR 314.80(c)(1)(i)Late submission of 15-day report
  5. 21 CFR 211.22(d)Procedures not in writing, fully followed
  6. 21 CFR 314.80(b)Failure to develop written procedures

Full citation text and observation details available on the Dashboard.

Other FDA inspections of Aurobindo Pharma USA Inc

4
DateClassificationOfficeProject area
June 4, 2026Not classifiedNew Jersey District Office
May 15, 2024OAICenter for Drug Evaluation and ResearchDrug Quality Assurance
December 12, 2014NAICenter for Drug Evaluation and ResearchDrug Quality Assurance
May 30, 2012NAICenter for Drug Evaluation and ResearchBioresearch Monitoring

Other documents for Aurobindo Pharma USA Inc

4
Document
FDA Inspection 1316082 · June 4, 2026 
FDA Inspection 1238442 · May 15, 2024 
FDA Inspection 908515 · December 12, 2014 
FDA Inspection 783745 · May 30, 2012 
View Company ProfileHave an account? Sign in to open in Dashboard

Or discuss it with

What you get

  1. A document

    One file.

    • One FDA document, such as a Form 483
    • Yours for life in your Library
    • Each has its own price
    here
  2. The profile

    All the documents, plus intelligence about the company.

    • Every Aurobindo Pharma USA Inc document on file
    • The KRA score, which a single document does not include
    • Observations and inspection history
  3. Access

    This, for every company on KeyPedia.

    • Combine profiles in one search
    • Search across any modality: products, industry types, drugs, devices and recalls
    • Track everything as it changes
    • Other agencies too, such as EMA, Health Canada and UK MHRA
    Browse free in KeyPedia Lite
KeyPedia
The intelligence layer for life sciences
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
Quick Links
HomePlatformUse CasesHardwarePricingResearchOur TechnologyFAQMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPrograms & Partnerships
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.